For financial advisers and professional investors only – not for distribution to retail investors.
June 05, 2024
This article has been written by Walter Scott & Partners Limited (‘Walter Scott’). The Walter Scott Global Equity Fund is proudly brought to you by Macquarie Professional Series.
In a world where the demand for healthcare is growing faster than supply of healthcare providers, the integration of advanced technology is becoming increasingly important. Although surgery has evolved significantly over the last 200 years, there’s still a long way to go. High complication rates partnered with a huge population still lacking access to basic surgical care, presents a promising outlook for the largely untapped robotic-assisted surgery (RAS) industry and a number of significant investment opportunities.
In 2020, nearly one million robotic-assisted surgeries were performed in the U.S. alone1, and this number has continued to increase. Robotic-assisted surgeries are revolutionising surgical procedures with their minimal invasive nature. The precision of robotic arms reduces risks and leads to faster recovery times and shorter hospital stays, enabling better patient outcomes. Additionally, for surgeons, surgical robots facilitate increased capabilities, greater consistency, and ultimately lead to happier surgeons.
Despite these advantages, the healthcare sector is yet to fully embrace and implement surgical robots on a large scale. The robotic-assisted surgery market could hit US$14billion globally by 20262, creating the potential for a promising growth opportunity for investors.
In this short video, Des Armstrong, Walter Scott Investment Manager, discusses the benefits of robotic surgery and the significant potential for this technology to improve the healthcare industry, especially with the enhancements of data and AI.
Watch time: ~3mins
Intuitive Surgical is thea global leader in robotic surgery systems used to facilitate minimally invasive surgery; by assisting in surgery with very small incisions and high magnification. The da Vinci system, designed and manufactured by Intuitive Surgical, demonstrates its precision by peeling a small grape and stitching it back together, showing how it is used for precision care during procedures while minimising damage to surrounding tissue.
Arguably, one of Intuitive’s greatest advantages over its peers is in the enormous amount of data it has accumulatedIntuitive Surgical has accumulated an enormous amount of data over more than 25 years. This includes everything from the raw video feeds of surgeries performed to which instruments are used for what and for how long, as well as the movements of the instruments and camera over time, as and when a surgeon uses an instrument and the precise wrist angle of their hands. There is even data available on the interactions between instruments and the tissue. With more than 14.2 million procedures performed to date across the da Vinci systems currently in use, the number of possible data points are almost infinite, and the integration of robotic with digital surgery becoming even more apparent.
If you’d like to read more about Intuitive Surgical, please reach out to your local Business Development Manager who can provide you with the Walter Scott Intuitive Surgical stock story.
1 National Institutes of Health (NIH)
2 Oliver Wyman, Positioning the industry for growth in robotic surgery
Important information: The Target Market Determination (TMD), available at macquarie.com/mam/tmd, includes a description of the class of consumers for whom the Fund is likely to be consistent with their objectives, financial situation and needs.
You might also like
Macquarie has appointed Walter Scott & Partners Limited (Walter Scott) as investment manager of the Walter Scott Global Equity Fund. Walter Scott is an investment management firm authorised and regulated in the United Kingdom by the Financial Conduct Authority in the conduct of investment business. Walter Scott is a wholly-owned subsidiary of The Bank of New York Mellon Corporation.
The Fund(s) mentioned above may have multiple classes of units on issue. A separate class of units is not a separate managed investment scheme.
This information has been prepared by Macquarie Investment Management Australia Limited (ABN 55 092 552 611 AFSL 238321) the issuer and responsible entity of the Fund(s) referred to above. This is general information only and does not take account of investment objectives, financial situation or needs of any person and before acting on this information, you should consider whether this information is appropriate for you. In deciding whether to acquire or continue to hold an investment in a Fund, an investor should consider the product disclosure statement for the relevant class of units in a Fund, if any, and the Website Disclosure Information available at macquarie.com/mam or by contacting us on 1800 814 523.
Nothing in this document constitutes a recommendation to buy, sell or hold any financial product, security or instrument.
Future results are impossible to predict. This document contains opinions, conclusions, estimates and other forward-looking statements which are, by their very nature, subject to various risks and uncertainties. Actual events or results may differ materially, positively or negatively, from those reflected or contemplated in such forward-looking statements.
Past performance information shown herein, is not a reliable indicator of future performance. No representation or warranty, express or implied, is made as to the suitability, accuracy, currency or completeness of the information, opinions and conclusions contained in this document. In preparing this document, reliance has been placed, without independent verification, on the accuracy and completeness of information available from external sources. To the maximum extent permitted by law, no member of the Macquarie Group nor its directors, employees or agents accept any liability for any loss arising from the use of this document, its contents or otherwise arising in connection with it.